Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

SPLIT/NASPGHAN COVID-19
Registry Reports

Week 10 -July 1 Report

Below is the SPLIT/NASPGHAN COVID registry Week Week 10 report: 4 new cases have been added including one patient with acute liver failure (pre-transplant)

  • There are 41 COVID positive patients: 21 with liver disease non-transplant and 20 post-liver transplant recipients
  • 34 have recovered and 6 are still active in their clinical course or pending further updates
  • 1 death has been reported, described by Dr. Hildreth on this listserv
  • Reported complications of chronic liver disease during COVID infection include: ascites in 6 patients, variceal bleeding in 1 patient and infection in 1 patient; all with chronic liver disease
Week 9 - June 26 Report

Click the button below for the SPLIT/NASPGHAN COVID registry Week 9 report: 2 new cases have been added

  • There are 37 COVID positive patients: 19 with chronic liver disease, 18 post-liver transplant recipients
  • 31 have recovered and 5 are still active in their clinical course or pending further updates
  • 1 death has been reported, described by Dr. Hildreth on this listserv
  • Reported complications of chronic liver disease during COVID infection include: ascites in 5 patients, variceal bleeding in 1 patient; all with chronic liver disease

 

Week 8 - June 22 Report

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 8 report: 3 new cases have been added

Week 7 - June 15 Report

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 7 report: 2 new cases have been added

Week 6 - June 8 Report

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 6 report: 2 new cases have been added

Week 5 - June 1 Report

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 5 report: 7 new cases have been added

Week 4 - May 25 Report

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 4 report: 6 new cases have been added

  • There are 23 COVID positive patients: 14 with chronic liver disease, 9 post-liver transplant recipients
  • 13 have recovered and 10 are still active in their clinical course or pending further updates
  • 2 patients with chronic liver disease required mechanical ventilation or HFOV
    • One patient who remains critically ill with NAFLD has required intubation, pressor support, CRRT and received COVID directed therapies (azithromycin and hydroxychloroquine, remdesivir, convalescent plasma, tocilizumab, steroids and eculizumab)
  • No deaths have been reported
  • Reported complications of chronic liver disease during COVID infection include: ascites in 4 patients, variceal bleeding in 1 patient and infection in 1 patient
Week 3 - May 15 Report

Below is the SPLIT/NASPGHAN COVID registry Week 3 report: 6 new cases have been added

  • There are 17 COVID positive patients: 9 with chronic liver disease, 8 post-liver transplant recipients
  • 13 have recovered and 4 are still active in their clinical course
  • 1 patient with chronic liver disease required mechanical ventilation
  • Reported complications of chronic liver disease during COVID infection include: ascites in 3 patients and variceal bleeding in 1 patient
  • No deaths were reported
  • COVID directed therapies included: hydroxychloroquine, azithromycin, IVIG, tocilizumab + sarilumab
Week 2 - May 6 Report

Below is the SPLIT/NASPGHAN COVID registry Week 2 report:

7 new cases have been added

  • There are 11 COVID positive patients: 4 with chronic liver disease, 7 post-liver transplant recipients
  • 9 have recovered and 2 are still active in their clinical course
  • No patients required mechanical ventilation
  • No deaths were reported
  • 1 patient received COVID directed therapy with azithromycin
Week 1 - May 1 Report

Below is the first week’s report for the SPLIT/NASPGHAN COVID registry which includes 4 total COVID positive patients. This includes:

  • 2 pediatric patients with chronic liver disease (biliary atresia and AIH)
  • 2 patients s/p liver transplant (for biliary atresia and ALF)

Of the above 4 patients:

  • 2 have clinically recovered and 2 are still active in their clinical course
  • One patient with biliary atresia s/p liver transplant who was <1 year out from transplant had tacrolimus trough levels reduced. The other patient who was >5 years out from liver transplant had no changes to their immunosuppression
  • Of the patients with chronic liver disease: one patient with autoimmune hepatitis had their dosage of azathioprine reduced, the other patient with biliary atresia was not any immunosuppressive therapies
  • None of the 4 patients received COVID directed treatment (for example: azithromycin, remdesivir, etc)

Please continue to share the registry broadly, particularly to our colleagues outside of North America. The registry can be accessed at: https://is.gd/naspghansplitliversurvey

We will continue to provide weekly updates through the SPLIT listserv.

Sincerely,

  • Noelle Ebel, Stanford University
  • Steven Lobritto, Chair of the SPLIT Quality Improvement and Clinical Care Committee, Columbia University
  • Vicky Ng, SPLIT President, University of Toronto
  • Mohit Kehar, Queens University
  • Mercedes Martinez, Chair of the NASPGHAN Hepatology Committee, Columbia University

Social

Contact

Staff Directory
+1-514-874-1717 x210
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

Society of Pediatric Liver Transplantation
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada